Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. (October 2013)

• Record Type: Journal Article
• Authors: Cignarelli, A.; Giorgino, F.; Vettor, R.
• Is Part Of: Archives of physiology and biochemistry. Volume 119:Number 4(2013)
• Page Start: 139
• Page End: 150
• Publication Date: 2013-10
• Subjects: Physiology -- Periodicals; Biochemistry -- Periodicals; Biophysics -- Periodicals; Biochemistry; Physiology; 571
• DOI: 10.3109/13813455.2013.796996
• Languages: English
• ISSNs: 1381-3455

Abstract

<abstract> <title>Abstract</title> <p>The close link between type 2 diabetes and excess body weight highlights the need to consider the effects on weight of different treatments used for correction of hyperglycaemia. Indeed, specific currently available diabetes therapies can cause weight gain, including insulin and its analogues, sulphonylureas, and thiazolidinediones, while others, such as metformin and the GLP-1 receptor agonists, can promote weight loss. Excess body weight in patients with diabetes is largely due to expansion of adipose tissue, and these drugs could interfere with the mechanisms underlying the expansion and differentiation of adipocyte precursors. Almost all anti-diabetes drugs could also potentially affect adipocyte metabolism directly, by modulating lipogenesis, lipolysis, and fat oxidation. This review will examine the available evidence for specific effects of various anti-diabetes drugs on adipose tissue development and function with the ultimate goal of increasing our understanding of how pharmacological agents can modulate energy balance and body fat.</p> </abstract>